Head-to-head evidence
Lurasidone vs Quetiapine (Seroquel)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Lurasidone
Marketed by Sumitomo Pharma
NCT00549718 · Phase 3 · completed
The study randomized approximately 500 participants to lurasidone 40, 80, or 120 mg or placebo and used quadruple masking of participants, clinicians, investigators, and outcome assessors. Its clinical primary endpoint, change in total PANSS score over 6 weeks, favored lurasidone overall versus placebo and was statistically significant (p<0.05).
Quetiapine (Seroquel)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00305422 · Phase 3 · completed
The study was randomized and double-blinded with an active risperidone comparator, but its small sample of 45 participants limits the strength of the evidence. The primary comparison was not reported, and the primary focus included cognitive and functional brain-activation measures rather than a clearly specified hard clinical endpoint.
Next expected readout: June 2028 · NCT05603104 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lurasidone's landscape · Quetiapine (Seroquel)'s landscape